Search

Displaying results 271 - 280 of 4539 in total
  1. Drug

    Bunamiodyl

    go.drugbank.com/drugs/DB04814
    ApprovedWithdrawn

    Withdrawn from the Canadian, US, and UK markets in 1963 due to nephropathy.

  2. Drug

    Dantron

    go.drugbank.com/drugs/DB04816
    ApprovedWithdrawn

    Withdrawn from the Canadian, US, and UK markets in 1998 due to genotoxicity.

  3. Drug

    Oxeladin

    go.drugbank.com/drugs/DB04822
    ApprovedWithdrawn

    Withdrawn from the Canadian, US, and UK markets in 1976 due to carcinogenicity.

  4. Drug

    Octasulfur

    go.drugbank.com/drugs/DB09353
    Approved

    People take sulfur by mouth for shortness of breath, allergies, swelling in the back of the throat (pharyngitis), high cholesterol, clogged arteries, menopause, and upper respiratory tract infections like

    Products: Liquimat Acne Treatment and Cover-UP
  5. Drug

    Oxybenzone

    go.drugbank.com/drugs/DB01428
    Approved

    It is used as an ingredient in sunscreen and other cosmetics because it absorbs UV-A ultraviolet rays.

    Mixtures: Chopper Chap Lip Balm, Chap - Grip SPF 15
  6. Drug

    Prenylamine

    go.drugbank.com/drugs/DB04825
    ApprovedWithdrawn

    Prenylamine was withdrawn from the Canadian, US, and UK markets in 1988 due to concerns regarding cardiac arrhythmias.

  7. Drug

    Octisalate

    go.drugbank.com/drugs/DB11062
    Approved

    Salicylates are weak UVB absorbers and they are generally used in combination with other UV filters. Octyl salicylate appears to have a good safety profile.

    Mixtures: Banana Boat Ultra Defence SPF 30 for UK, Fruit Of The Earth Block-UP Sport 30 Bug Repelling
  8. Drug

    Depemokimab

    go.drugbank.com/drugs/DB18846
    ApprovedInvestigational

    aged 12 years and older. … [A275338] Approved by the FDA on December 16, 2025, depemokimab is indicated as an add-on maintenance treatment for severe asthma characterized by an eosinophilic phenotype in adult and paediatric patients

  9. Drug

    Moxifloxacin

    go.drugbank.com/drugs/DB00218
    ApprovedInvestigational

    Bayer AG developed the drug (initially called BAY 12-8039) and it is marketed worldwide (as the hydrochloride) under the brand name Avelox (in some countries also Avalox) for oral treatment.

    Mixtures: TQ OFTAMOX D UD®, TQ OFTAMOX® D UDProducts: TQ OFTAMOX® UD
  10. Drug

    Berahyaluronidase alfa

    go.drugbank.com/drugs/DB22790
    ApprovedInvestigational

    This combination was approved by the US FDA in September 2025 and is indicated for various solid tumors in adults and pediatric patients 12 years and older, offering a subcutaneous option for indications